Canopy Growth Q1 Earnings: Four Segments Grew. The Factor Stack Tells a Different Story.

The press release leads with 13% net revenue growth, contributions from every business unit, and a narrowed net loss. That's the narrative frame. The factor stack tells a more complicated story, and the peer comparison makes it even clearer.

Canopy Growth (CGC) reported Q1 fiscal 2027 results today — net revenue of CAD 81.2 million, up 13% year-over-year from CAD 72.1 million. Canada medical grew 22%, adult-use grew 10%, international cannabis grew 10%, and Storz & Bickel grew 6%. Adjusted gross margin (a non-GAAP measure excluding inventory step-up charges) improved to 31% from 25%. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough proxy for operating cash generation) narrowed by 59% to a loss of CAD 3.2 million.

That sounds like broad-based improvement. But the numbers you don't see in the headline are the ones that drive the rating.

Growth: Improving, but the base was artificially weak

The 13% revenue growth is real. Every segment contributed. The EPS of CAD -0.03 beat the consensus estimate of CAD -0.04 by 50%. The net loss of CAD 14.6 million was 68% smaller than a year ago.

But the prior-year base in Q1 FY2026 was depressed by cost-cutting disruptions and weak Storz & Bickel sales, which had fallen 25% year-over-year at that time. Beating a trough quarter is not the same as building a trajectory. The trailing twelve-month revenue growth rate sits at 9.0% — positive, but far from the kind of acceleration that re-ranks a stock within its sector. And the quarter-over-quarter revenue decline of 6.1% relative to Q4 FY2026 tells you the growth engine is not yet self-sustaining.

Profitability: Margin expansion is the real story — so far

This is where the quarter actually gets interesting. Adjusted gross margin expanding from 25% to 31% is a six-point move, and it was not an accounting artifact. Storz & Bickel's gross margin jumped from 29% to 48%, driven by cost rationalization and recovery of certain U.S. tariffs. The cannabis segment margin improved from 24% to 26%. That kind of margin expansion matters because it shows operating leverage starting to work — higher sales volumes absorbing fixed costs.

But the TTM gross margin of 24.5% and operating margin of -56.8% tell you how far the company still has to go. The operating margin number looks extreme because it absorbs massive SG&A and cultivation overhead against relatively small revenues. The path from a 31% adjusted gross margin in one quarter to profitability on an operating basis is not short.

Safety: The balance sheet is the best part

Cash of CAD 336.6 million against total debt of roughly CAD 217 million (derived from the $301.8M total debt figure less long-term instruments, net of cash at $261.4M reported by the data service, though the press release states CAD 336.6M in cash) gives Canopy Growth net negative debt — more cash than obligations. Debt-to-equity sits at 33.5%, which is low. The company is not in danger of running out of money. That's a structural floor.

The flip side: free cash flow burned through CAD 25.7 million this quarter, worse than the CAD 11.6 million outflow a year ago, driven by working capital timing. TTM free cash flow stands at -CAD 59.4 million. The balance sheet buys time; it doesn't generate returns. Return on invested capital (ROIC) is negative 19.1%, and return on equity (ROE) is negative 45.3%. These are not numbers that suggest the business is earning its way forward yet.

Valuation and Peer Comparison: The discount is structural

At a market cap of $394 million, CGC trades at 1.9x trailing sales and 0.79x book value. Enterprise value is $300 million after netting cash. The P/E ratio is negative and not useful — the company is not earning.

Now put that next to the peer set. Cronos Group (CRON), the closest U.S.-listed cannabis peer, trades at a $1.15 billion market cap and 7.2x trailing sales — nearly four times Canopy's sales multiple. Cronos is also not profitable (TTM P/E of negative 631), but the market is pricing in its Israel cannabis franchise, vape market leadership in Canada, and stronger cash position. The valuation gap between CGC and CRON is not a mispricing anomaly; it reflects different risk profiles, different growth trajectories, and the market's assessment of which company is closer to sustainable profitability.

Canopy's valuation discount is real. Whether it's attractive depends on your view of whether the margin expansion we're seeing now is a trend or a one-off recovery from an unusually weak comparison period.

Momentum: The technical picture is still bearish

The stock trades at $0.93, down 35.5% over the trailing year and down 18.2% year-to-date. It's below both the 50-day moving average ($0.97) and the 200-day moving average ($1.11). RSI sits at 48.3 — neutral, not oversold. MACD is negative. The stock has declined 9.5% over 120 days and 4.3% over the past 20 days. There is no momentum support here. A beat on earnings didn't produce a sustained reaction in the share price.

AInvest cross-check

AInvest's aggregate signal labels CGC as a Hold, with a fundamental rating of 2.01 (on a scale where higher is better) and a liquidity rating of 7.84. That's consistent with the factor stack: improving on some dimensions, still structurally challenged on others.

What the factor stack says

Growth is positive but not accelerating. Profitability is improving directionally — the margin expansion is the strongest signal in the quarter. Safety is adequate. Momentum is negative. Valuation is deeply discounted relative to peers, but for reasons the market has already priced in.

This is not a Strong Buy setup. It's not a Sell either. The improving margin trajectory, combined with a net cash balance and a valuation below book value, puts CGC in a watch category — not an add category. The stock is a bet on Canadian cannabis normalization and operational execution, not on immediate financial inflection.

What would change the rating? Two things: (1) consecutive quarters of positive adjusted EBITDA, which would signal that margin expansion is durable rather than seasonal, and (2) a reversal in the momentum picture — a break above the 50-day moving average on volume that suggests institutional accumulation rather than retail support. Neither is happening right now.

When uncertainty is this high, the response is more structure, not more conviction. If you're already positioned in Canadian cannabis exposure, this quarter doesn't require a change. If you're looking to add, wait for the factor stack to show more before leaning in. The margin improvement is real. The path to profitability is still long.

Next earnings: November 6, 2026.